February 2012

The FDA approved a subcutaneous formulation of Bristol-Myers Squibb's Orencia (abatacept) for the treatment of moderately to severely active rheumatoid arthritis in adults.

Why are REMS not standardized today? Our columnist offers insight into the problem and how to lead specialty pharmacy forward.

The International Classification of Diseases codes will undergo significant changes to address the limitations of coding hospital inpatient procedures and patient medical conditions. Here's what you'll need to know to stay abreast.

The exploration of the freedom to operate in the specialty biopharmaceutical market, which requires specific steps and processes.

The FDA approved Genentech's Zelboraf (vermurafenib) for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation.

We welcome our new editorial advisory board member, a leader and innovator in the industry.

Increasing customer satisfaction leads to the likelihood of customer loyalty. Nurses can provide value-added services for specialty pharmacies, manufacturers, and payers that promote customer loyalty.

New drugs and drugs in the pipeline for gout have changed the treatment for this painful disease, one of the oldest documented diseases. Here's an update on what's new and what specialty pharmacists need to know as they counsel patients for gout.

Once patients receive their new organs, the specialty pharmacy can help them navigate through lifelong, complex transplant therapy. Here's a look at one such program.

Copay organizations play an important role in helping patients obtain their medications and have become integral partner with specialty pharmacies as they work together to support different therapies.

Orphan drug development has taken off as this segment of the industry has seen impressive growth. Here's an expert analysis of the orphan market by an industry leader outlining the challenges and opportunities.

This dynamic market is seeing a lot of growth, changes, and challenges. Specialty pharmacists can tackle the tough issues and raise the bar on greater levels of efficiency, accountability, and service while curtailing costs.

Payer response to new entrants to the multiple sclerosis (MS) market is mixed as some believe that there remain meaningful, major unmet needs in the MS category, according to The Zitter Group's Spring 2011 Managed Care Biologics and Injectables Index.

Managing the collection and reporting process for clinical assessments is paramount to ensuring the integrity of data collected, clinical decisions, and reporting requirements.